Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

FokI polymorphism in vitamin D receptor gene and risk of breast cancer among Caucasian women

verfasst von: Jin-lu Shan, Nan Dai, Xue-qin Yang, Cheng-yuan Qian, Zhen-zhou Yang, Feng Jin, Mengxia Li, Dong Wang

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Vitamin D plays a central role in cellular proliferation, apoptosis induction, and tumor growth suppression. The vitamin D receptor (VDR) is a crucial mediator for the cellular effects of vitamin D. A series of epidemiological studies have examined the association between the VDR FokI polymorphism and breast cancer risk, but the findings remain inconclusive. Fifteen eligible case–control studies involving 15,681 cancer cases and 20,632 control subjects were identified through searching PubMed, Embase, and Web of Science. Odds ratios (ORs) and 95 % confidence intervals (CIs) were used to assess the association. Heterogeneity across studies was examined with the chi-square-based Q test and the I 2 index. Begg’s and Egger’s test were also performed to determine publication bias. All statistical data were analyzed by STATA software. The combined estimates did not show significant risks correlated with the FokI polymorphism. However, we found an increased risk in the subgroup analysis by source of control (OR = 1.11, 95 % CI = 1.01–1.22; heterogeneity test: P = 0.116, I 2 = 0.0 % for ff vs FF; OR = 1.10, 95 % CI = 1.01–1.21; heterogeneity test: P = 0.832, I 2 = 0.0 % for ff vs Ff + FF). This meta-analysis suggests that the presence of FokI polymorphism may contribute to the risk of breast cancer in Caucasians.
Literatur
1.
Zurück zum Zitat Uitterlinden AG et al. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143–56.PubMedCrossRef Uitterlinden AG et al. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143–56.PubMedCrossRef
2.
Zurück zum Zitat Bertone-Johnson ER et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1991–7.PubMedCrossRef Bertone-Johnson ER et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1991–7.PubMedCrossRef
3.
Zurück zum Zitat Crew KD et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila). 2009;2(6):598–604.CrossRef Crew KD et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila). 2009;2(6):598–604.CrossRef
4.
Zurück zum Zitat Janowsky EC et al. Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr. 1999;2(3):283–91.PubMedCrossRef Janowsky EC et al. Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr. 1999;2(3):283–91.PubMedCrossRef
5.
Zurück zum Zitat Lowe LC et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005;41(8):1164–9.PubMedCrossRef Lowe LC et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005;41(8):1164–9.PubMedCrossRef
6.
Zurück zum Zitat Jensen SS et al. Inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 2001;15(8):1370–80.PubMed Jensen SS et al. Inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol. 2001;15(8):1370–80.PubMed
7.
Zurück zum Zitat Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684–700.PubMedCrossRef Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684–700.PubMedCrossRef
8.
Zurück zum Zitat Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet. 1989;1(8631):188–91.PubMedCrossRef Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet. 1989;1(8631):188–91.PubMedCrossRef
9.
Zurück zum Zitat Hansen CM et al. Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci. 2001;6:D820–48.PubMedCrossRef Hansen CM et al. Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci. 2001;6:D820–48.PubMedCrossRef
10.
Zurück zum Zitat Guyton KZ, Kensler TW, Posner GH. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev. 2003;61(7):227–38.PubMedCrossRef Guyton KZ, Kensler TW, Posner GH. Vitamin D and vitamin D analogs as cancer chemopreventive agents. Nutr Rev. 2003;61(7):227–38.PubMedCrossRef
11.
Zurück zum Zitat Polly P et al. Identification of a vitamin D3 response element in the fibronectin gene that is bound by a vitamin D3 receptor homodimer. J Cell Biochem. 1996;60(3):322–33.PubMedCrossRef Polly P et al. Identification of a vitamin D3 response element in the fibronectin gene that is bound by a vitamin D3 receptor homodimer. J Cell Biochem. 1996;60(3):322–33.PubMedCrossRef
12.
Zurück zum Zitat Liu M et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996;10(2):142–53.PubMedCrossRef Liu M et al. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996;10(2):142–53.PubMedCrossRef
13.
Zurück zum Zitat Polly P et al. 1 alpha,25-dihydroxyvitamin D3 receptor as a mediator of transrepression of retinoid signaling. J Cell Biochem. 1997;67(3):287–96.PubMedCrossRef Polly P et al. 1 alpha,25-dihydroxyvitamin D3 receptor as a mediator of transrepression of retinoid signaling. J Cell Biochem. 1997;67(3):287–96.PubMedCrossRef
14.
Zurück zum Zitat Berger U et al. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab. 1988;67(3):607–13.PubMedCrossRef Berger U et al. Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab. 1988;67(3):607–13.PubMedCrossRef
15.
Zurück zum Zitat Cui Y, Rohan TE. Vitamin D, calcium, and breast cancer risk: a review. Cancer Epidemiol Biomarkers Prev. 2006;15(8):1427–37.PubMedCrossRef Cui Y, Rohan TE. Vitamin D, calcium, and breast cancer risk: a review. Cancer Epidemiol Biomarkers Prev. 2006;15(8):1427–37.PubMedCrossRef
16.
Zurück zum Zitat Barroso E et al. Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies. BMC Cancer. 2008;8:385.PubMedCentralPubMedCrossRef Barroso E et al. Genetic analysis of the vitamin D receptor gene in two epithelial cancers: melanoma and breast cancer case-control studies. BMC Cancer. 2008;8:385.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Chen WY et al. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2335–9.PubMedCrossRef Chen WY et al. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2335–9.PubMedCrossRef
18.
Zurück zum Zitat Gapska P et al. Vitamin D receptor variants and breast cancer risk in the polish population. Breast Cancer Res Treat. 2009;115(3):629–33.PubMedCrossRef Gapska P et al. Vitamin D receptor variants and breast cancer risk in the polish population. Breast Cancer Res Treat. 2009;115(3):629–33.PubMedCrossRef
19.
Zurück zum Zitat Sinotte M et al. Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: association replication in two case-control studies within French Canadian population. Endocr Relat Cancer. 2008;15(4):975–83.PubMedCentralPubMedCrossRef Sinotte M et al. Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: association replication in two case-control studies within French Canadian population. Endocr Relat Cancer. 2008;15(4):975–83.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Anderson LN et al. Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1708–17.PubMedCrossRef Anderson LN et al. Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev. 2011;20(8):1708–17.PubMedCrossRef
21.
Zurück zum Zitat Curran JE et al. Association of A vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer. 1999;83(6):723–6.PubMedCrossRef Curran JE et al. Association of A vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer. 1999;83(6):723–6.PubMedCrossRef
22.
Zurück zum Zitat Guy M et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004;10(16):5472–81.PubMedCrossRef Guy M et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004;10(16):5472–81.PubMedCrossRef
23.
Zurück zum Zitat John EM et al. Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J Epidemiol. 2007;166(12):1409–19.PubMedCrossRef John EM et al. Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J Epidemiol. 2007;166(12):1409–19.PubMedCrossRef
25.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.PubMed
26.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRef DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.PubMedCrossRef
28.
Zurück zum Zitat McCullough ML et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res. 2007;9(1):R9.PubMedCentralPubMedCrossRef McCullough ML et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res. 2007;9(1):R9.PubMedCentralPubMedCrossRef
29.
30.
Zurück zum Zitat McKay JD et al. Vitamin D receptor polymorphisms and breast cancer risk: results from the National cancer institute breast and prostate cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 2009;18(1):297–305.PubMedCrossRef McKay JD et al. Vitamin D receptor polymorphisms and breast cancer risk: results from the National cancer institute breast and prostate cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 2009;18(1):297–305.PubMedCrossRef
31.
Zurück zum Zitat Engel LS et al. Vitamin D receptor gene haplotypes and polymorphisms and risk of breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1856–67.PubMedCentralPubMedCrossRef Engel LS et al. Vitamin D receptor gene haplotypes and polymorphisms and risk of breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1856–67.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Rollison DE et al. Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S.A. Breast Cancer Res Treat. 2012;132(2):683–91.PubMedCentralPubMedCrossRef Rollison DE et al. Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S.A. Breast Cancer Res Treat. 2012;132(2):683–91.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Fuhrman BJ et al. Sunlight, polymorphisms of vitamin D-related genes and risk of breast cancer. Anticancer Res. 2013;33(2):543–51.PubMedCentralPubMed Fuhrman BJ et al. Sunlight, polymorphisms of vitamin D-related genes and risk of breast cancer. Anticancer Res. 2013;33(2):543–51.PubMedCentralPubMed
34.
Zurück zum Zitat Mishra DK et al. Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. PLoS One. 2013;8(3):e57967.PubMedCentralPubMedCrossRef Mishra DK et al. Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. PLoS One. 2013;8(3):e57967.PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Shahbazi S et al. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Med Oncol. 2013;30(1):393.PubMedCrossRef Shahbazi S et al. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Med Oncol. 2013;30(1):393.PubMedCrossRef
36.
Zurück zum Zitat Banerjee P, Chatterjee M. Antiproliferative role of vitamin D and its analogs—a brief overview. Mol Cell Biochem. 2003;253(1–2):247–54.PubMedCrossRef Banerjee P, Chatterjee M. Antiproliferative role of vitamin D and its analogs—a brief overview. Mol Cell Biochem. 2003;253(1–2):247–54.PubMedCrossRef
37.
Zurück zum Zitat Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr. 2004;80(6 Suppl):1721S–4S.PubMed Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr. 2004;80(6 Suppl):1721S–4S.PubMed
39.
Zurück zum Zitat Arai H et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res. 1997;12(6):915–21.PubMedCrossRef Arai H et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res. 1997;12(6):915–21.PubMedCrossRef
40.
Zurück zum Zitat Raimondi S et al. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30(7):1170–80.PubMedCrossRef Raimondi S et al. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30(7):1170–80.PubMedCrossRef
41.
Zurück zum Zitat Tang C et al. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2009;117(2):391–9.PubMedCrossRef Tang C et al. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2009;117(2):391–9.PubMedCrossRef
42.
Zurück zum Zitat Economopoulos KP, Sergentanis TN. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat. 2010;120(1):211–6.PubMedCrossRef Economopoulos KP, Sergentanis TN. Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat. 2010;120(1):211–6.PubMedCrossRef
43.
Zurück zum Zitat Thakkinstian A et al. A method for meta-analysis of molecular association studies. Stat Med. 2005;24(9):1291–306.PubMedCrossRef Thakkinstian A et al. A method for meta-analysis of molecular association studies. Stat Med. 2005;24(9):1291–306.PubMedCrossRef
Metadaten
Titel
FokI polymorphism in vitamin D receptor gene and risk of breast cancer among Caucasian women
verfasst von
Jin-lu Shan
Nan Dai
Xue-qin Yang
Cheng-yuan Qian
Zhen-zhou Yang
Feng Jin
Mengxia Li
Dong Wang
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1462-z

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.